AccurKardia
AccurKardia: An AI-based cardiac analysis firm offering cloud-based, FDA-cleared ECG interpretation software.
Founded
2019AccurKardia: An AI-based cardiac analysis firm offering cloud-based, FDA-cleared ECG interpretation software.
Founded with the mission to enable world-class cardiac care in a connected world, AccurKardia is an AI-based cardiac analysis company specializing in ECG-led diagnostics. Their flagship product, AccurECG, is an FDA-cleared, cloud-based software designed for fully automated ECG interpretation and detection of up to 13 arrhythmias. The software is device-agnostic and accessible via API, making it versatile for various healthcare applications. AccurKardia aims to unlock the value of ECG signals for broad diagnostics and disease management, ultimately improving clinical outcomes globally.
AccurKardia has garnered attention and support from notable investors and industry leaders in the healthcare technology space. The company's key achievements include obtaining FDA clearance for AccurECG, which underscores its clinical-grade reliability and effectiveness. By integrating advanced AI technology into cardiac diagnostics, AccurKardia has made significant strides in enhancing the accuracy and efficiency of arrhythmia detection, thereby contributing to better patient care and potentially saving lives on a large scale.
Companies similar to AccurKardia include ZBeats, Cardiac Insight, Medicalgorithmics and Anumana.
AccurKardia was founded in 2019.
AccurKardia's headquarters is located in New York City, NY, US.
AccurKardia's most recent funding round was for $2.7M (USD) in June 2023.
As of Jun 20, 2023, AccurKardia has disclosed funding of $4.3M (USD). Undisclosed round amounts are excluded.
AccurKardia has 9 employees as of Feb 5, 2024.
anumana.net
